Premium
Pharmacokinetics and important drug–drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti‐viral therapy
Author(s) -
Cohen Elizabeth,
Liapakis AnnMarie
Publication year - 2018
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/sdi.12763
Subject(s) - medicine , kidney disease , drug , hepatitis c , hepatitis c virus , population , renal replacement therapy , intensive care medicine , kidney transplantation , hepatitis , pharmacokinetics , antiviral drug , transplantation , disease , pharmacology , immunology , virus , environmental health
Hepatitis C direct acting antiviral (DAA) therapy has evolved so that infected patients with advanced chronic kidney disease (CKD) can now anticipate the opportunity for sustained virologic response equivalent to that of the broader population of patients with hepatitis C. This has revolutionized the field of transplantation as it relates to renal transplant candidates with hepatitis C and the use of grafts from hepatitis C virus (HCV) viremic donors. In treating this population of patients, special consideration must be given to the timing of anti‐viral therapy and drug–drug interactions. Herein we review the pharmacokinetics of HCV DAA therapy in the setting of CKD and chronic renal replacement therapy. Highlighted are drug/drug interactions with special attention to therapies utilized in advanced CKD and immunosuppressants.